share_log

華領醫藥-B：委任執行董事

HUA MEDICINE-B: APPOINTMENT OF EXECUTIVE DIRECTOR

香港交易所 ·  Dec 29, 2023 03:36
Summary by Moomoo AI
華領醫藥宣布，張怡博士自2024年1月1日起被委任為執行董事。張博士自2018年起在公司擔任高級職務，並於2021年11月成為首席醫學官。他的服務合約為期三年，並可由任何一方提前終止。張博士的薪酬將不會因此新職位而增加，但他將獲得執行董事職責相關的合理開支報銷。此外，張博士確認在公司無任何股份權益，也未在其他上市公司擔任董事職務。董事會對張博士的加入表示熱烈歡迎，並確認此次委任符合上市規則要求。
華領醫藥宣布，張怡博士自2024年1月1日起被委任為執行董事。張博士自2018年起在公司擔任高級職務，並於2021年11月成為首席醫學官。他的服務合約為期三年，並可由任何一方提前終止。張博士的薪酬將不會因此新職位而增加，但他將獲得執行董事職責相關的合理開支報銷。此外，張博士確認在公司無任何股份權益，也未在其他上市公司擔任董事職務。董事會對張博士的加入表示熱烈歡迎，並確認此次委任符合上市規則要求。
Huahlin Pharmaceuticals announced that Dr. Zhang Yi has been appointed as Executive Director with effect from January 1, 2024. Dr. Zhang has held a senior position at the company since 2018 and became Chief Medical Officer in November 2021. His service contract is for three years and can be terminated in advance by any party. Dr. Zhang's salary will not increase as a result of the new position, but he will receive reasonable reimbursement of expenses related to his duties as a director. In addition, Dr. Zhang confirmed that he did not have any equity interest in the company and did not serve as a director in other listed companies. The Board of Directors warmly welcomes the addition of Dr. Zhang and confirms that this appointment complies with the requirements of the Listing Rules.
Huahlin Pharmaceuticals announced that Dr. Zhang Yi has been appointed as Executive Director with effect from January 1, 2024. Dr. Zhang has held a senior position at the company since 2018 and became Chief Medical Officer in November 2021. His service contract is for three years and can be terminated in advance by any party. Dr. Zhang's salary will not increase as a result of the new position, but he will receive reasonable reimbursement of expenses related to his duties as a director. In addition, Dr. Zhang confirmed that he did not have any equity interest in the company and did not serve as a director in other listed companies. The Board of Directors warmly welcomes the addition of Dr. Zhang and confirms that this appointment complies with the requirements of the Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more